Effect of salmeterol on polymorphonuclear leukocyte (PMNL) chemiluminescence in vitro.
Although beta-agonists remain an important aspect of the treatment of asthma, their role has recently been questioned. Salmeterol has recently been developed as a beta-agonist with prolonged bronchodilator action. Using lucigenin-enhanced chemiluminescence, we have shown that salmeterol inhibits this aspect of phagocyte function in vitro in a concentration-dependent manner. However, salmeterol differs from classical beta 2-agonists in that at concentrations between 10(-5) and 10(-3) mol/L, its effects on phagocytes cannot be completely reversed by washing the cells or by propranolol. The effects on phagocytes may not therefore be explicable on the basis of beta-adrenergic mechanisms alone.
Ramage
L
L
Department of Pathology, University of Dundee, Ninewells Hospital and Medical School, Scotland.
Blair
A L
AL
Cree
I A
IA
Dhillon
D P
DP
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D007700:Kinetics; D008163:Luminescent Measurements; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D011433:Propranolol / Q000494:pharmacology; D000068299:Salmeterol Xinafoate; D013726:Terbutaline / Q000494:pharmacology; D013997:Time Factors; D014969:Xanthine Oxidase / Q000378:metabolism; D015054:Zymosan / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D015054:Zymosan; D011433:Propranolol; D014969:Xanthine Oxidase; D013726:Terbutaline; D000420:Albuterol